Table 1.
| HIV− (n=1,265) | HIV+ (n=1,396) | |||||
|---|---|---|---|---|---|---|
| Not frail (n=1187) | Frail (n=78) | P a | Not frail (n=1270) | Frail (n=126) | P a | |
| Cardiovascular risk scores, median (IQR) | ||||||
| ATP-III FRS, %b | 6 (2–10) | 10 (5–16) | <0.001 | 4 (1–8) | 6 (3–12) | <0.001 |
| ACC/AHA PCE, %b,c | 6 (4–11) | 10 (7–19) | <0.001 | 6 (3–9) | 8 (4–14) | <0.001 |
| Cardiovascular risk scores, strata | ||||||
| ATP-III FRS, %b | <0.001 | 0.001 | ||||
| Low risk (<10%) | 813 (68%) | 32 (41%) | 983 (77%) | 79 (63%) | ||
| Moderate risk (10–20%) | 344 (29%) | 40 (51%) | 259 (20%) | 42 (33%) | ||
| High risk (>20%) | 30 (3%) | 6 (8%) | 28 (2%) | 5 (4%) | ||
| ACC/AHA PCE, %b,c | <0.001 | <0.001 | ||||
| Low risk (<7.5%) | 539 (57%) | 19 (29%) | 568 (64%) | 48 (46%) | ||
| High risk (≥7.5%) | 406(43%) | 46 (71%) | 325 (36%) | 56 (54%) | ||
| Cardiovascular risk score components, median (IQR) | ||||||
| Age | 50 (42–57) | 54 (45–58) | 0.03 | 45 (38–51) | 50 (44–55) | <0.001 |
| Total cholesterol, mg/dL | 188 (165–216) | 186 (160–220) | 0.86 | 180 (153–208) | 167 (147–187) | 0.006 |
| HDL cholesterol, mg/dL | 49 (41–58) | 46 (39–55) | 0.10 | 43 (36–53) | 40 (35–50) | 0.09 |
| SBP, mmHg | 128(118–137) | 130 (121–140) | 0.09 | 126 (117–134) | 128 (115–138) | 0.58 |
| Cardiovascular risk score components, strata | ||||||
| Race (Black or African American) | 0.02 | 0.55 | ||||
| No | 929 (78%) | 52 (67%) | 848 (67%) | 88 (70%) | ||
| Yes | 258 (22%) | 26 (33%) | 422 (33%) | 38 (30%) | ||
| Current smoker | 0.003 | 0.03 | ||||
| No | 888 (75%) | 46 (59%) | 830 (65%) | 70 (56%) | ||
| Yes | 299 (25%) | 32 (41%) | 440 (35%) | 56 (44%) | ||
| Antihypertensive medication use | <0.001 | <0.001 | ||||
| No | 923 (78%) | 44 (56%) | 1011 (80%) | 75 (60%) | ||
| Yes | 264 (22%) | 34 (44%) | 259 (20%) | 51 (40%) | ||
| Diabetes | 0.001 | 0.001 | ||||
| No | 1105 (93%) | 64 (82%) | 1176 (93%) | 105 (83%) | ||
| Yes | 82 (7%) | 14 (18%) | 94 (7%) | 21 (17%) | ||
ACC/AHA PCE: American College of Cardiology/American Heart Association pooled cohort equations; ATP-III FRS: Adult Treatment Program III Framingham risk score; HIV: human immunodeficiency virus; IQR: interquartile range; MACS: Multicenter AIDS Cohort Study; SBP: systolic blood pressure
a
Comparisons of continuous variables by Wilcoxon rank sum and categorical variables by Fisher’s exact test
b
ATP-III FRS and ACC/AHA PCE are in men 20–79 and 40–79 years of age, respectively
c
ACC/AHA PCE were available for 1010 (80%) HIV− and 997 (71%) HIV+ men at the index visit